Skip to main content

Jenne Kyle's Form 4 filing

Ionis Pharmaceuticals Inc (IONS) · filed Mar 11, 2026

Accession no.
0000874015-26-000142
Filed
Mar 11, 2026
Trade date
Mar 10, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.83M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jenne KyleCIK 0001791857Officer (EVP, Chf GL Pdt Str Ofcr)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 10, 2026Common StockMOption exerciseAcquired+32,602$46.10+$1,502,952.248,991Direct
Mar 10, 2026Common StockSSaleDisposed−21,191$75.50−$1,599,920.527,800Direct
Mar 10, 2026Common StockSSaleDisposed−16,086$76.30−$1,227,361.811,714Direct
Mar 10, 2026Common StockMOption exerciseAcquired+4,675$34.69+$162,175.7516,389Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2026Common StockMOption exerciseDisposed−4,675$0.00$014,025Direct
Mar 10, 2026Common StockMOption exerciseDisposed−32,602$0.00$032,601Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)